These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 36345767

  • 1. Bone metastases in prostate cancer - Gallium-68-labeled prostate-specific membrane antigen or Fluorine 18 sodium fluoride PET/computed tomography - the better tracer?
    Agrawal A, Natarajan A, Mithun S, Bakshi G, Joshi A, Murthy V, Menon S, Purandare N, Shah S, Puranik A, Choudhury S, Prakash G, Pal M, Maitre P, Prabhash K, Noronha V, Rangarajan V.
    Nucl Med Commun; 2022 Dec 01; 43(12):1225-1232. PubMed ID: 36345767
    [Abstract] [Full Text] [Related]

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.
    Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.
    Hell J Nucl Med; 2019 Dec 01; 22(1):6-9. PubMed ID: 30843003
    [Abstract] [Full Text] [Related]

  • 3. Comparison of [68Ga]Ga-PSMA-11 PET/CT with [18F]NaF PET/CT in the evaluation of bone metastases in metastatic prostate cancer patients prior to radionuclide therapy.
    Uprimny C, Svirydenka A, Fritz J, Kroiss AS, Nilica B, Decristoforo C, Haubner R, von Guggenberg E, Buxbaum S, Horninger W, Virgolini IJ.
    Eur J Nucl Med Mol Imaging; 2018 Oct 01; 45(11):1873-1883. PubMed ID: 29766246
    [Abstract] [Full Text] [Related]

  • 4. A Prospective Comparison of 18F-Sodium Fluoride PET/CT and PSMA-Targeted 18F-DCFBC PET/CT in Metastatic Prostate Cancer.
    Harmon SA, Bergvall E, Mena E, Shih JH, Adler S, McKinney Y, Mehralivand S, Citrin DE, Couvillon A, Madan RA, Gulley JL, Mease RC, Jacobs PM, Pomper MG, Turkbey B, Choyke PL, Lindenberg ML.
    J Nucl Med; 2018 Nov 01; 59(11):1665-1671. PubMed ID: 29602821
    [Abstract] [Full Text] [Related]

  • 5. Is there a utility of adding skeletal imaging to 68-Ga-prostate-specific membrane antigen-PET/computed tomography in initial staging of patients with high-risk prostate cancer?
    Raju S, Sharma A, Patel C, Sahoo R, Das CJ, Kumar S, Sharma A, Kumar R.
    Nucl Med Commun; 2020 Nov 01; 41(11):1183-1188. PubMed ID: 32796451
    [Abstract] [Full Text] [Related]

  • 6. 68Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis.
    von Eyben FE, Picchio M, von Eyben R, Rhee H, Bauman G.
    Eur Urol Focus; 2018 Sep 01; 4(5):686-693. PubMed ID: 28753806
    [Abstract] [Full Text] [Related]

  • 7. 68Ga-PSMA-PET/CT in comparison with 18F-fluoride-PET/CT and whole-body MRI for the detection of bone metastases in patients with prostate cancer: a prospective diagnostic accuracy study.
    Dyrberg E, Hendel HW, Huynh THV, Klausen TW, Løgager VB, Madsen C, Pedersen EM, Pedersen M, Thomsen HS.
    Eur Radiol; 2019 Mar 01; 29(3):1221-1230. PubMed ID: 30132104
    [Abstract] [Full Text] [Related]

  • 8. Prospective Comparison of PET Imaging with PSMA-Targeted 18F-DCFPyL Versus Na18F for Bone Lesion Detection in Patients with Metastatic Prostate Cancer.
    Rowe SP, Li X, Trock BJ, Werner RA, Frey S, DiGianvittorio M, Bleiler JK, Reyes DK, Abdallah R, Pienta KJ, Gorin MA, Pomper MG.
    J Nucl Med; 2020 Feb 01; 61(2):183-188. PubMed ID: 31451492
    [Abstract] [Full Text] [Related]

  • 9. Prospective comparison of 68Ga-PSMA PET/CT, 18F-sodium fluoride PET/CT and diffusion weighted-MRI at for the detection of bone metastases in biochemically recurrent prostate cancer.
    Zacho HD, Nielsen JB, Afshar-Oromieh A, Haberkorn U, deSouza N, De Paepe K, Dettmann K, Langkilde NC, Haarmark C, Fisker RV, Arp DT, Carl J, Jensen JB, Petersen LJ.
    Eur J Nucl Med Mol Imaging; 2018 Oct 01; 45(11):1884-1897. PubMed ID: 29876619
    [Abstract] [Full Text] [Related]

  • 10. Intra-individual comparison of prostate-specific membrane antigen positron emission tomography/computed tomography versus bone scan in detecting skeletal metastasis at prostate cancer diagnosis.
    Shanmugasundaram R, Saad J, Heyworth A, Wong V, Pelecanos A, Arianayagam M, Canagasingham B, Ferguson R, Goolam AS, Khadra M, Kam J, Ko R, McCombie S, Varol C, Winter M, Mansberg R, Nguyen D, Bui C, Loh H, Le K, Roberts MJ.
    BJU Int; 2024 Feb 01; 133 Suppl 3():25-32. PubMed ID: 37943964
    [Abstract] [Full Text] [Related]

  • 11. Total-Body 68Ga-PSMA-11 PET/CT for Bone Metastasis Detection in Prostate Cancer Patients: Potential Impact on Bone Scan Guidelines.
    Pomykala KL, Czernin J, Grogan TR, Armstrong WR, Williams J, Calais J.
    J Nucl Med; 2020 Mar 01; 61(3):405-411. PubMed ID: 31541035
    [Abstract] [Full Text] [Related]

  • 12. 68Ga-PSMA PET/CT Replacing Bone Scan in the Initial Staging of Skeletal Metastasis in Prostate Cancer: A Fait Accompli?
    Lengana T, Lawal IO, Boshomane TG, Popoola GO, Mokoala KMG, Moshokoa E, Maes A, Mokgoro NP, Van de Wiele C, Vorster M, Sathekge MM.
    Clin Genitourin Cancer; 2018 Oct 01; 16(5):392-401. PubMed ID: 30120038
    [Abstract] [Full Text] [Related]

  • 13. Primary lymph-node staging with 68Ga-PSMA PET in high-risk prostate cancer: pathologic correlation with extended pelvic lymphadenectomy specimens.
    Corona-Montes VE, González-Cuenca E, Fernández-Noyola G, Olarte-Casas MA, Bobadilla-Salazar D, Medrano-Urtecho HM, Asimakopoulos AD.
    Urol Oncol; 2021 Aug 01; 39(8):494.e1-494.e6. PubMed ID: 33223371
    [Abstract] [Full Text] [Related]

  • 14. A Multicenter Prospective Clinical Trial of 68Gallium PSMA HBED-CC PET-CT Restaging in Biochemically Relapsed Prostate Carcinoma: Oligometastatic Rate and Distribution Compared With Standard Imaging.
    McCarthy M, Francis R, Tang C, Watts J, Campbell A.
    Int J Radiat Oncol Biol Phys; 2019 Jul 15; 104(4):801-808. PubMed ID: 30890448
    [Abstract] [Full Text] [Related]

  • 15. 68Ga-PSMA-11 PET/CT derived quantitative volumetric tumor parameters for classification and evaluation of therapeutic response of bone metastases in prostate cancer patients.
    Schmidkonz C, Cordes M, Goetz TI, Prante O, Kuwert T, Ritt P, Uder M, Wullich B, Goebell P, Bäuerle T.
    Ann Nucl Med; 2019 Oct 15; 33(10):766-775. PubMed ID: 31338731
    [Abstract] [Full Text] [Related]

  • 16. An 89Zr-Labeled PSMA Tracer for PET/CT Imaging of Prostate Cancer Patients.
    Dietlein F, Kobe C, Vázquez SM, Fischer T, Endepols H, Hohberg M, Reifegerst M, Neumaier B, Schomäcker K, Drzezga AE, Dietlein M.
    J Nucl Med; 2022 Apr 15; 63(4):573-583. PubMed ID: 34326129
    [Abstract] [Full Text] [Related]

  • 17. 68Ga-PSMA PET/CT in prostate cancer patients - patterns of disease, benign findings and pitfalls.
    Keidar Z, Gill R, Goshen E, Israel O, Davidson T, Morgulis M, Pirmisashvili N, Ben-Haim S.
    Cancer Imaging; 2018 Nov 01; 18(1):39. PubMed ID: 30382889
    [Abstract] [Full Text] [Related]

  • 18. 99mTc-HDP bone scintigraphy and 18F-sodiumfluoride PET/CT in primary staging of patients with prostate cancer.
    Wondergem M, van der Zant FM, Knol RJJ, Burgers AMG, Bos SD, de Jong IJ, Pruim J.
    World J Urol; 2018 Jan 01; 36(1):27-34. PubMed ID: 29043431
    [Abstract] [Full Text] [Related]

  • 19. Observer Agreement and Accuracy of 18F-Sodium Fluoride PET/CT in the Diagnosis of Bone Metastases in Prostate Cancer.
    Zacho HD, Fonager RF, Nielsen JB, Haarmark C, Hendel HW, Johansen MB, Mortensen JC, Petersen LJ.
    J Nucl Med; 2020 Mar 01; 61(3):344-349. PubMed ID: 31481577
    [Abstract] [Full Text] [Related]

  • 20. Bone scintigraphy as a gatekeeper for the detection of bone metastases in patients with prostate cancer: comparison with Ga-68 PSMA PET/CT.
    Caglar M, Tuncel M, Yildiz E, Karabulut E.
    Ann Nucl Med; 2020 Dec 01; 34(12):932-941. PubMed ID: 32975741
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.